Bristol Myers Squibb (BMY) Return on Capital Employed (2009 - 2026)

Bristol Myers Squibb has disclosed Return on Capital Employed across 17 years of filings, most recently posting 6.84% for Q1 2026.

• In Q1 2026, Return on Capital Employed rose 479.0% year-over-year to 6.84%; the TTM figure through Mar 2026 stood at 6.84% (up 479.0% YoY), while the FY2025 annual figure was 6.79%, up 2509.0% from the prior year.
• Return on Capital Employed eased to 6.84% in Q1 2026, from 6.58% in the prior quarter.
• Over the last five years, Return on Capital Employed for BMY reached as high as 1.88% in Q1 2023 and fell as low as 32.22% in Q4 2024.
• The 5-year median for Return on Capital Employed is 6.58% (2025), against an average of 10.25%.
• Annual changes were most pronounced in 2024 — Return on Capital Employed sank 2904 bps — and 2025, when it surged 2564 bps.
• A 5-year view of Return on Capital Employed shows it stood at 3.21% in 2022, then grew by 1 bps to 3.18% in 2023, then tumbled by 915 bps to 32.22% in 2024, then soared by 80 bps to 6.58% in 2025, then retreated by 4 bps to 6.84% in 2026.
• According to Business Quant data, Return on Capital Employed over the past three periods registered 6.84%, 6.58%, and 9.78% for Q1 2026, Q4 2025, and Q3 2025 respectively.